[{"id":"94c408ac-7175-4009-9855-94101a5bc215","acronym":"M23-385","url":"https://clinicaltrials.gov/study/NCT05599984","created_at":"2022-10-31T13:56:57.345Z","updated_at":"2025-02-25T14:03:07.565Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05599984 - M23-385","lead_sponsor":"AbbVie","biomarkers":" EGFR • SEZ6","pipe":" | ","alterations":" EGFR mutation • IDH wild-type","tags":["EGFR • SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/05/2022","start_date":" 12/05/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-19"},{"id":"4bdac475-2ce7-43c7-9fc6-1b82deed752b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376800","created_at":"2022-05-17T12:54:19.363Z","updated_at":"2025-02-25T14:08:51.835Z","phase":"Phase 1","brief_title":"A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma","source_id_and_acronym":"NCT05376800","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type • IDH wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-02-18"},{"id":"624dd6dc-cc83-4a6f-bc36-82aa836ef4f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05429502","created_at":"2022-06-23T16:00:07.143Z","updated_at":"2025-02-25T14:08:56.594Z","phase":"Phase 1/2","brief_title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","source_id_and_acronym":"NCT05429502","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MYCN • SMARCB1","pipe":" | ","alterations":" IDH wild-type","tags":["MYCN • SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kisqali (ribociclib) • topotecan"],"overall_status":"Recruiting","enrollment":" Enrollment 231","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 10/15/2027","primary_completion_date":" 10/15/2027","study_txt":" Completion: 01/28/2028","study_completion_date":" 01/28/2028","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"1ed1c0e3-9fae-4441-b5f9-6a5bb4623646","acronym":"","url":"https://clinicaltrials.gov/study/NCT04968366","created_at":"2021-07-20T14:52:28.893Z","updated_at":"2025-02-25T15:44:32.669Z","phase":"Phase 1","brief_title":"Safety \u0026 Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","source_id_and_acronym":"NCT04968366","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-11"},{"id":"451a8a7f-851d-493a-9270-889080e917a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05086497","created_at":"2021-10-21T13:53:08.372Z","updated_at":"2025-02-25T15:19:19.323Z","phase":"","brief_title":"WBSI Guided Personalized Delivery of TTFields","source_id_and_acronym":"NCT05086497","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 01/15/2023","start_date":" 01/15/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-11"},{"id":"0af43381-6afd-4912-9b0c-5801c2007fc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05432804","created_at":"2022-06-27T14:54:16.638Z","updated_at":"2025-02-25T16:46:08.151Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","source_id_and_acronym":"NCT05432804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xpovio (selinexor)"],"overall_status":"Recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 03/20/2023","start_date":" 03/20/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-06"},{"id":"fb005881-4dad-4aee-8405-d3b9ee7b7d75","acronym":"","url":"https://clinicaltrials.gov/study/NCT05463848","created_at":"2022-07-19T15:55:14.520Z","updated_at":"2025-02-25T16:17:57.365Z","phase":"Phase 2","brief_title":"Surgical Pembro +/- Olaparib W TMZ for RGBM","source_id_and_acronym":"NCT05463848","lead_sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","biomarkers":" EGFR • TERT","pipe":" | ","alterations":" EGFR mutation • EGFR amplification • IDH wild-type","tags":["EGFR • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR amplification • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/21/2022","start_date":" 10/21/2022","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-02-06"},{"id":"597196ff-832d-47d8-abb2-6fd446401e06","acronym":"ACNS1721","url":"https://clinicaltrials.gov/study/NCT03581292","created_at":"2021-01-18T17:37:11.394Z","updated_at":"2025-02-25T16:52:13.824Z","phase":"Phase 2","brief_title":"Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations","source_id_and_acronym":"NCT03581292 - ACNS1721","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" IDH wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • veliparib (ABT-888)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 10/16/2025","study_completion_date":" 10/16/2025","last_update_posted":"2025-02-04"},{"id":"c5be4f65-abfd-49b2-9e6b-92e20f00da7f","acronym":"STING","url":"https://clinicaltrials.gov/study/NCT03048084","created_at":"2021-01-18T15:00:39.333Z","updated_at":"2025-02-25T16:51:48.926Z","phase":"Phase 4","brief_title":"Seizure Treatment in Glioma","source_id_and_acronym":"NCT03048084 - STING","lead_sponsor":"Leiden University Medical Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation • IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-02-04"},{"id":"f228ffce-69d8-4696-a61e-6222a211f51d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05188508","created_at":"2022-01-12T14:53:32.609Z","updated_at":"2025-02-25T16:17:09.399Z","phase":"Phase 2","brief_title":"Pembrolizumab, Olaparib, and Temozolomide for People with Glioma","source_id_and_acronym":"NCT05188508","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type","tags":["EGFR • BRCA1 • BRCA2 • HRD • CDKN2A • FGFR • CDK12 • CDKN2B • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • BRIP1 mutation • RAD51C mutation • RAD51B mutation • BARD1 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"0761f5fc-4fb6-468e-bb3d-390adb9bdabf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113705","created_at":"2023-11-02T15:12:45.694Z","updated_at":"2025-02-25T17:26:31.436Z","phase":"","brief_title":"Imaging and Biological Markers for Prediction and Identification of Glioblastoma Pseudoprogression: a Prospective Study.","source_id_and_acronym":"NCT06113705","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" IDH1 • IDH2 • MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1 • IDH2 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-31"},{"id":"2e2ffa16-9364-47ec-af17-c174c6bba967","acronym":"ARISTOCRAT","url":"https://clinicaltrials.gov/study/NCT05629702","created_at":"2022-11-29T14:57:14.668Z","updated_at":"2024-07-02T16:34:25.626Z","phase":"Phase 2","brief_title":"ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids","source_id_and_acronym":"NCT05629702 - ARISTOCRAT","lead_sponsor":"University of Birmingham","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Sativex (nabiximols)"],"overall_status":"Recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-17"},{"id":"eb5c9ee3-620e-48d0-bab8-f8f2914ede1d","acronym":"NRG-BN010","url":"https://clinicaltrials.gov/study/NCT04729959","created_at":"2021-03-09T19:55:01.650Z","updated_at":"2024-07-02T16:34:27.180Z","phase":"Phase 2","brief_title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT04729959 - NRG-BN010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • MGMT • TERT","pipe":" | ","alterations":" EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation","tags":["EGFR • MGMT • TERT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR amplification • TERT mutation • IDH wild-type • TERT promoter mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Actemra IV (tocilizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-11"},{"id":"450196e9-e0ad-47bf-a736-4b3fdabb7b6e","acronym":"NCI-2019-03057","url":"https://clinicaltrials.gov/study/NCT03953898","created_at":"2021-01-18T19:27:50.729Z","updated_at":"2024-07-02T16:34:37.850Z","phase":"Phase 2","brief_title":"Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation","source_id_and_acronym":"NCT03953898 - NCI-2019-03057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation • IDH1 R132H • IDH2 R172K • IDH1 R132C • IDH wild-type • IDH1 R132 • IDH1 R132G • IDH2 R140Q • IDH1 R132L • IDH1 R132S • IDH1 R132V • IDH2 R172 • IDH2 R172G"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 08/04/2020","start_date":" 08/04/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-06-06"},{"id":"e726abe0-9a61-4e1d-8970-9b7613e8839f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522142","created_at":"2021-01-18T17:20:30.581Z","updated_at":"2024-07-02T16:34:37.560Z","phase":"Phase 1","brief_title":"A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies","source_id_and_acronym":"NCT03522142","lead_sponsor":"Incyte Corporation","biomarkers":" FLT3 • MSI • IDH1 • IDH2","pipe":" | ","alterations":" MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type","tags":["FLT3 • MSI • IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • FLT3-ITD mutation • FLT3 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB81776"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-06"},{"id":"3c4b70e5-0095-4941-b867-c448ada0131d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879250","created_at":"2023-05-30T14:05:05.692Z","updated_at":"2024-07-02T16:34:59.705Z","phase":"Phase 2","brief_title":"WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT05879250","lead_sponsor":"Northwestern University","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" RAS wild-type • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":" Primary completion: 12/27/2027","primary_completion_date":" 12/27/2027","study_txt":" Completion: 12/27/2028","study_completion_date":" 12/27/2028","last_update_posted":"2024-05-31"},{"id":"caca578c-aaca-49e5-a97d-ca67554ac90d","acronym":"CLINGLIO","url":"https://clinicaltrials.gov/study/NCT04250922","created_at":"2021-01-18T20:39:26.321Z","updated_at":"2024-07-02T16:34:59.713Z","phase":"Phase 2/3","brief_title":"LAM561 With RT and TMZ for Adults With Glioblastoma","source_id_and_acronym":"NCT04250922 - CLINGLIO","lead_sponsor":"Laminar Pharmaceuticals","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Minerval (idroxioleic acid)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 10/15/2024","primary_completion_date":" 10/15/2024","study_txt":" Completion: 05/30/2025","study_completion_date":" 05/30/2025","last_update_posted":"2024-05-31"},{"id":"b56f4287-89ee-4b31-a0fe-61bc9ba09fe4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986851","created_at":"2023-08-14T15:10:00.555Z","updated_at":"2024-07-02T16:35:00.485Z","phase":"Phase 2","brief_title":"Azeliragon in MGMT Unmethylated Glioblastoma","source_id_and_acronym":"NCT05986851","lead_sponsor":"Cantex Pharmaceuticals","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azeliragon (TTP488)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/12/2023","start_date":" 09/12/2023","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-29"},{"id":"12ef23c8-0f04-4348-90aa-89217bc8e0c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04555577","created_at":"2021-07-05T17:32:33.242Z","updated_at":"2024-07-02T16:35:03.500Z","phase":"Phase 1","brief_title":"Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma","source_id_and_acronym":"NCT04555577","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • peposertib (M3814)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 09/20/2020","start_date":" 09/20/2020","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-05-15"},{"id":"6fd39586-a5ba-42d4-9b04-4797a9ca665f","acronym":"GESTALT","url":"https://clinicaltrials.gov/study/NCT05342883","created_at":"2022-04-25T22:54:38.331Z","updated_at":"2024-07-02T16:35:03.480Z","phase":"Phase 4","brief_title":"GammaTile and Stupp in Newly Diagnosed GBM","source_id_and_acronym":"NCT05342883 - GESTALT","lead_sponsor":"GT Medical Technologies, Inc.","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132H • IDH wild-type • IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH wild-type • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-15"},{"id":"77eb3cd1-2540-4b18-b06d-2e8b7aee2b46","acronym":"NCI-2018-00872","url":"https://clinicaltrials.gov/study/NCT03452930","created_at":"2021-07-05T17:12:08.426Z","updated_at":"2024-07-02T16:35:03.679Z","phase":"Phase 1","brief_title":"Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma","source_id_and_acronym":"NCT03452930 - NCI-2018-00872","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinostamustine (EDO-S101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 08/13/2018","start_date":" 08/13/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-15"},{"id":"3b885732-0c6b-4c16-beb1-fbc5553cef67","acronym":"GlioVax","url":"https://clinicaltrials.gov/study/NCT03395587","created_at":"2021-01-18T16:45:21.670Z","updated_at":"2024-07-02T16:35:04.022Z","phase":"Phase 2","brief_title":"Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT03395587 - GlioVax","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 03/06/2018","start_date":" 03/06/2018","primary_txt":" Primary completion: 11/06/2026","primary_completion_date":" 11/06/2026","study_txt":" Completion: 03/06/2027","study_completion_date":" 03/06/2027","last_update_posted":"2024-05-14"},{"id":"12564864-7d8c-467b-ba26-fc5db317bd65","acronym":"","url":"https://clinicaltrials.gov/study/NCT05120960","created_at":"2021-11-16T13:54:01.498Z","updated_at":"2024-07-02T16:35:09.062Z","phase":"Phase 1","brief_title":"A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors","source_id_and_acronym":"NCT05120960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Tepmetko (tepotinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 04/12/2024","primary_completion_date":" 04/12/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-17"}]